D Callegaro-Filho1, D M Gershenson2, A M Nick2, M F Munsell3, P T Ramirez2, P J Eifel4, E D Euscher5, R M Marques6, S M Nicolau6, K M Schmeler7. 1. Department of Medical Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil; Division of Gynecologic Oncology, Universidade Federal de São Paulo, São Paulo, Brazil. 2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Division of Gynecologic Oncology, Universidade Federal de São Paulo, São Paulo, Brazil. 7. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: kschmele@mdanderson.org.
Abstract
OBJECTIVE: Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare disease with a poor prognosis. SCCOHT has recently been shown to be associated with SMARCA4 gene mutations as well as molecular and genetic similarities to malignant rhabdoid tumors (MRT). The objective of our study is to describe the clinical characteristics, treatment modalities and outcomes of 47 patients with SCCOHT. METHODS: We performed a retrospective analysis of 47 patients with SCCOHT evaluated at MD Anderson Cancer Center between 1990 and 2014. Medical records were reviewed for demographic information, pathologic findings, treatment regimens and outcomes. RESULTS: Median age at diagnosis was 30 years (range 5-46). All patients underwent surgery with unilateral salpingo-oophorectomy (USO) performed in 26 patients (55%), and hysterectomy with bilateral salpingooophorectomy (BSO) in 21 patients (45%). Sixteen patients (34.0%) had stage I disease, six (12.8%) stage II, 23 (48.9%) stage III, and two patients (4.3%) had stage IV disease. Information on adjuvant treatment was available for 43 patients: 83.3% received chemotherapy alone, 9.5% chemotherapy followed by radiotherapy, 2.4% chemoradiation, and 4.8% did not receive any adjuvant therapy. Median follow-up was 13.2 months (range, 0.1 to 210.7) with a median overall survival of 14.9 months. Multi-agent chemotherapy and radiotherapy were associated with a better prognosis. CONCLUSION: Our findings suggest that aggressive therapy including multi-agent chemotherapy and possibly radiotherapy may extend survival. Further study is needed to improve outcomes in these patients including the adoption of systemic therapies used in MRT as well as the development of novel agents targeting specific mutations.
OBJECTIVE: Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare disease with a poor prognosis. SCCOHT has recently been shown to be associated with SMARCA4 gene mutations as well as molecular and genetic similarities to malignant rhabdoid tumors (MRT). The objective of our study is to describe the clinical characteristics, treatment modalities and outcomes of 47 patients with SCCOHT. METHODS: We performed a retrospective analysis of 47 patients with SCCOHT evaluated at MD Anderson Cancer Center between 1990 and 2014. Medical records were reviewed for demographic information, pathologic findings, treatment regimens and outcomes. RESULTS: Median age at diagnosis was 30 years (range 5-46). All patients underwent surgery with unilateral salpingo-oophorectomy (USO) performed in 26 patients (55%), and hysterectomy with bilateral salpingooophorectomy (BSO) in 21 patients (45%). Sixteen patients (34.0%) had stage I disease, six (12.8%) stage II, 23 (48.9%) stage III, and two patients (4.3%) had stage IV disease. Information on adjuvant treatment was available for 43 patients: 83.3% received chemotherapy alone, 9.5% chemotherapy followed by radiotherapy, 2.4% chemoradiation, and 4.8% did not receive any adjuvant therapy. Median follow-up was 13.2 months (range, 0.1 to 210.7) with a median overall survival of 14.9 months. Multi-agent chemotherapy and radiotherapy were associated with a better prognosis. CONCLUSION: Our findings suggest that aggressive therapy including multi-agent chemotherapy and possibly radiotherapy may extend survival. Further study is needed to improve outcomes in these patients including the adoption of systemic therapies used in MRT as well as the development of novel agents targeting specific mutations.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Petar Jelinic; Jennifer J Mueller; Narciso Olvera; Fanny Dao; Sasinya N Scott; Ronak Shah; JianJiong Gao; Nikolaus Schultz; Mithat Gonen; Robert A Soslow; Michael F Berger; Douglas A Levine Journal: Nat Genet Date: 2014-03-23 Impact factor: 38.330
Authors: Leora Witkowski; Jian Carrot-Zhang; Steffen Albrecht; Somayyeh Fahiminiya; Nancy Hamel; Eva Tomiak; David Grynspan; Emmanouil Saloustros; Javad Nadaf; Barbara Rivera; Catherine Gilpin; Ester Castellsagué; Rachel Silva-Smith; François Plourde; Mona Wu; Avi Saskin; Madeleine Arseneault; Rouzan G Karabakhtsian; Elizabeth A Reilly; Frederick R Ueland; Anna Margiolaki; Kitty Pavlakis; Sharon M Castellino; Janez Lamovec; Helen J Mackay; Lawrence M Roth; Thomas M Ulbright; Tracey A Bender; Vassilis Georgoulias; Michel Longy; Andrew Berchuck; Marc Tischkowitz; Inga Nagel; Reiner Siebert; Colin J R Stewart; Jocelyne Arseneau; W Glenn McCluggage; Blaise A Clarke; Yasser Riazalhosseini; Martin Hasselblatt; Jacek Majewski; William D Foulkes Journal: Nat Genet Date: 2014-03-23 Impact factor: 38.330
Authors: William D Foulkes; Blaise A Clarke; Martin Hasselblatt; Jacek Majewski; Steffen Albrecht; W Glenn McCluggage Journal: J Pathol Date: 2014-05-20 Impact factor: 7.996
Authors: P Pautier; V Ribrag; P Duvillard; A Rey; I Elghissassi; I Sillet-Bach; P Kerbrat; F Mayer; A Lesoin; B Brun; H Crouet; J C Barats; P Morice; C Lhommé Journal: Ann Oncol Date: 2007-08-30 Impact factor: 32.976
Authors: H Woopen; J Sehouli; K Pietzner; S Darb-Esfahani; E I Braicu; C Fotopoulou Journal: Eur J Obstet Gynecol Reprod Biol Date: 2012-08-18 Impact factor: 2.435
Authors: John J Wallbillich; Alpa M Nick; Pedro T Ramirez; Jack L Watkins; Elizabeth D Euscher; Kathleen M Schmeler Journal: Gynecol Oncol Case Rep Date: 2012-02-13
Authors: Donato Callegaro-Filho; Thomas W Burke; Patricia J Eifel; Pedro T Ramirez; Elizabeth E Euscher; Kathleen M Schmeler Journal: Gynecol Oncol Rep Date: 2014-12-29
Authors: Elizabeth K Lee; Katharine M Esselen; David L Kolin; Larissa J Lee; Ursula A Matulonis; Panagiotis A Konstantinopoulos Journal: JCO Precis Oncol Date: 2020-06-24
Authors: Yamicia D Connor; Diana Miao; Douglas I Lin; Cynthia Hayne; Brooke E Howitt; John L Dalrymple; Kimberly R DeLeonardis; Michele R Hacker; Katharine M Esselen; Meghan Shea Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482
Authors: Rosalba De Nola; Edoardo Di Naro; Luca Maria Schonauer; Giuseppe Lucarelli; Michele Battaglia; Maria Grazia Fiore; Salvatore Andrea Mastrolia; Giuseppe Loverro Journal: Medicine (Baltimore) Date: 2018-01 Impact factor: 1.889